The board of directors of Kontafarma China Holdings Limited announced that Mr. Huang Yu has been re-designated from an executive Director to a non-executive Director of the Company with effect from 19 April 2024 due to his other work commitments. He will concurrently cease to be the
president of the Group and a member of each of the executive committee of the Board and the share dealing committee of the Board. Mr. Huang, aged 55, was appointed as an executive Director of the Company and the president of the Group on 15 March 2014 and 3 September 2020 respectively. He is also a director of certain subsidiaries of the Company. Mr. Huang served as the chairman of the Board of the Company from July 2014 to September 2020. He is currently an executive director and general manager of Shenzhen Aorongxin Investment Development Co. Ltd. the chairman of the supervisory committee of Penghua Fund Management Co. Ltd. and a director of the GuoDu Securities Co. Ltd. Mr. Huang had also been a
director and senior management of several listed companies, including the chairman of the board and a non-executive director of Neo-Neon Holdings Limited Mr. Bai Pingyan has decided to retire from the position as the executive Director with effect from the conclusion of the AGM to devote more
time to his other commitment. He will concurrently cease to be the chairman of the Board and the chairman of each of the Executive Committee, the nomination committee of the Board, the Share Dealing Committee and the investment committee of the Board. Mr. Chai Hongjie has decided to retire from the position as the executive Director with effect from the conclusion of the AGM to devote more time to other business of the Shenzhen Waranty group. He will concurrently cease to be a member of each of the Executive Committee and the Share Dealing Committee; Mr. Jiang Chaowen has decided to retire from the position as the executive Director with effect from the conclusion of the AGM to devote more time to his other commitment, but will continue to serve as the president and the chairman of Tongfang Pharmaceutical Group Co. Ltd. and the chairman of Chongqing Kangle Pharmaceutical Co. Ltd. both being the subsidiaries of the Group, to overseeand manage the pharmaceutical business segment of the Group. He will concurrently cease to be the chief executive officer of the Group, as well as a member of each of the Executive Committee, the Share Dealing Committee, and the risks management committee of the Board. Mr. Chan Sze Chung has notified the Board of his decision to retire as an independent non-executive Director by rotation at the AGM in accordance with the Articles of Association, and to not offer himself for re-election, after serving the Board for over 12 years, in order to devote more time to his other commitments. With effect from the conclusion of the AGM, Mr. Chan will also cease to be the chairman of the audit committee of the Board and a member of each of the Nomination Committee, the Risks Management Committee, the Investment Committee and the remuneration committee of the Board. Mr. Zhang Ruibin has notified the Board of his decision to retire as an independent non-executive Director by rotation at the AGM in accordance with the Articles of Association, and to not offer himself for re-election, after serving the Board for over 9 years, in order to devote more time to his other commitments. With effect from the conclusion of the AGM, Mr. Zhang Ruibin will also cease to be the chairman of the Remuneration Committee and a member of each of the Audit Committee, the Nomination Committee, the Risks Management Committee and the Investment Committee; and Mr. Zhang Junxi Jack has notified the Board of his decision to retire as an independent non-executive Director by rotation at the AGM in accordance with the Articles of Association, and to not offer himself for re-election, after serving the Board for over 8 years, in order to devote more time to his other commitments. With effect from the conclusion of the AGM, Mr. Zhang Junxi Jack will also cease to be the chairman of the Risks Management Committee and a member of each of the Audit Committee, the Remuneration Committee and the Nomination Committee.